Received Feb 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 3 | 943186 | IM |
Patient was administered a vaccine that was later identified as expired at the time of administration. The patient was informed of the expiration status and verbalized understanding. No adverse reactions or immediate complications were observed or reported. Provider made aware and discussed follow up with patient. A return to clinic date was provided to the patient.
STI related
Asthma and Heirsprung disease
not currently taking any medications daily or intermittently
Tree-nut allergy
None